Evaluation of the Safety and Efficacy of Voice Prosthesis in Voice Reconstruction After Total Laryngectomy

Atos Medical

Status: Active, not recruiting

Conditions: Laryngectomy; Status

Treatments: Device: Provox Vega Voice prosthesis

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT05482815

AMAB-FYN-1.0

Details and patient eligibility

About

The objective of the study is to evaluate the clinical safety and efficacy of voice prosthesis for voice reconstruction after total laryngectomy in China.

Main outcome will be the assessment of pronunciation effect (subjective auditory assessment).

Enrollment: 80 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• The age is greater than 18 years; the gender is not limited
• Performed total laryngectomy;
• No voice prosthesis has been installed
• Be able to take care of themselves mentally and physically, and have good hand coordination ability
• With healthy wall sharing with trachea and esophagus
• The patient has a desire to restore articulation function
• Can speak Mandarin and have a certain reading ability (equivalent to primary school education)
• The subject is fully aware of the benefits and risks of this trial and is willing to participate in and sign the informed consent form

Exclusion criteria

• There is serious respiratory system disease or defect
• There is a serious skin disease in the tracheostoma
• Obvious intelligence and mental disorder
• Tracheostoma is narrow and needs cannula implantation
• Patients with limitation of mouth opening and other subjects with dyslalia or language disorders (such as subjects with sequelae of cerebral infarction, etc.)
• Patients with severe respiratory disease, cardiopulmonary disease (e.g., severe arrhythmia, persons with slow ventricular rate (ventricular rate <50 beats/ min), acute phase of myocardial infarction and severe heart failure), disturbances of blood coagulation (coagulation index PT, APTT, INR> 1.5 times of the normal upper limit), septicemia and other patients not suitable
• Patients with severe diseases of liver and renal function (liver function index, alanine aminotransferase (ALT), aspartate aminotransferase (AST)> 2 times of normal upper limit, renal function index, urine creatinine (Cr), blood urea nitrogen (BUN)> 2 times of normal upper limit);
• Patients with local recurrence of tumor or metastatic tumor
• If the patient has received esophageal articulation training, the time of training and using esophagus to speech should be less than 6 months
• Women planning to have child, in lactation or pregnancy during the whole clinical study
• Participated in other clinical trials within 1 month
• Other candidates the investigators think not appropriate

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

80 participants in 1 patient group

Voice Prosthesis

Experimental group

Description:

Subjects receive a Voice prosthesis using the Provox Puncture Set, then undergo an articulation training program (3 weeks). The voice prosthesis is replaced after 3 months and 6 months.

Treatment:

Device: Provox Vega Voice prosthesis